Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COVID-19 disease severity and indicator of the need for mechanical ventilation, ARDS and mortality
Research
[키워드] 30-Day mortality
95% CI
acute COVID-19
acute respiratory distress
adjusted
age
ARDS
AUC
Biomarker
calculated
changes in
clinician
Comorbidity
Concentration
control group
COVID-19
COVID-19 convalescent patients
COVID-19 disease severity
COVID-19 patient
COVID-19 patients
COVID-19 severity
COVID-19 symptoms
critically ill patients
cut-off
determine
dialysis
disease
disease severity
elevated
ELISA
Gender
Germany
healthy control
healthy volunteer
High-flow nasal oxygen
IMPROVE
Increases
information
Inpatient
intensive care unit
male
management
mechanical ventilation
Mortality
need for oxygen
Non-COVID-19
Observational cohort study
Odds ratio
Organ failure
organ support
Patient
Pneumonia
predict
prediction
primary endpoint
qSOFA
RAGE
receptor
Respiratory failure
Result
risk
secondary endpoint
serum
severe disease
severity
shown
SOFA
Soluble RAGE
subsequent
supplementary material
Support
syndrome
therapy
Variation
was measured
were measured
with COVID-19
[DOI] 10.1186/s13613-021-00836-2 PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s13613-021-00836-2 PMC 바로가기 [Article Type] Research